AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Akari Therapeutics plc ADR (0.01 USD)
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG003PMV510
8.23▲ 0.13 (1.54%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
8.10
Day's Range
7.84 – 8.45
52-Week Range
0.12 – 29.32
Volume
14.4K
Avg Volume
47.4K
Share Statistics
Shares Outstanding
Employees
5
Exchange
XNAS
Listed
2012-12-07
Share count as of August 13, 2026

Akari Therapeutics plc ADR (0.01 USD) (AKTX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Akari Therapeutics plc ADR (0.01 USD) (AKTX)
What is Akari Therapeutics plc ADR (0.01 USD)'s Market Cap?
Akari Therapeutics plc ADR (0.01 USD)'s Market Cap is $1.3T, based on as-reported figures from SEC (XBRL) filings.
What is Akari Therapeutics plc ADR (0.01 USD)'s Enterprise Value?
Akari Therapeutics plc ADR (0.01 USD)'s Enterprise Value is $1.3T, based on as-reported figures from SEC (XBRL) filings.
What is Akari Therapeutics plc ADR (0.01 USD)'s EV / EBITDA?
Akari Therapeutics plc ADR (0.01 USD)'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Akari Therapeutics plc ADR (0.01 USD)'s Net Income (TTM)?
Akari Therapeutics plc ADR (0.01 USD)'s Net Income (TTM) is -$31.0M, based on as-reported figures from SEC (XBRL) filings.
What is Akari Therapeutics plc ADR (0.01 USD)'s EBITDA?
Akari Therapeutics plc ADR (0.01 USD)'s EBITDA is -$31.0M, based on as-reported figures from SEC (XBRL) filings.
What is Akari Therapeutics plc ADR (0.01 USD)'s Diluted EPS (TTM)?
Akari Therapeutics plc ADR (0.01 USD)'s Diluted EPS (TTM) is -0.00, based on as-reported figures from SEC (XBRL) filings.
What is Akari Therapeutics plc ADR (0.01 USD)'s Net Debt?
Akari Therapeutics plc ADR (0.01 USD)'s Net Debt is -$7.7M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · AKTXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Non-cash impairment charge——
Asset Impairment Charges—
Loss from operations
Other income (expense):
Interest expense
Gain on settlement of current liabilities
Change in fair value of warrant liabilities
Non-Operating Income (Expense)
Total other income (expense), net
Net loss before tax
Net loss
Earnings Per Share (Basic)—
Earnings Per Share (Diluted)—